Advertisement
Singapore markets close in 5 hours 34 minutes

  • Straits Times Index

    3,273.92
    -13.83 (-0.42%)
     

  • Nikkei

    37,780.35
    +151.87 (+0.40%)
     

  • Hang Seng

    17,622.28
    +337.74 (+1.95%)
     

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • Bitcoin USD

    64,439.41
    +190.91 (+0.30%)
     

  • CMC Crypto 200

    1,390.47
    +7.90 (+0.57%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,345.10
    +2.60 (+0.11%)
     

  • Crude Oil

    83.84
    +0.27 (+0.32%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,572.55
    +3.30 (+0.21%)
     

  • Jakarta Composite Index

    7,117.42
    -37.87 (-0.53%)
     

  • PSE Index

    6,553.22
    -21.66 (-0.33%)
     

Novo Nordisk's Smash-Hit Drug Could Become Even More Profitable. Here's Why.

Alex Carchidi, The Motley Fool
·4-min read
Novo Nordisk's Smash-Hit Drug Could Become Even More Profitable. Here's Why.

Novo Nordisk's (NYSE: NVO) semaglutide is everywhere in the news, and for good reason. Thanks to its ability to help people lose weight and control their diabetes symptoms, its moneymaking potential is practically off the charts. At the moment, semaglutide is indicated to treat obesity and type 2 diabetes, and it's available in a few different formulations, which vary depending on the dosage and whether it's administered via a weekly injection or a once-per-day pill.

Continue reading